Medco Commits $20 Mil. To Part D Development, Implementation Costs
This article was originally published in The Pink Sheet Daily
Capital investment will be used to develop the infrastructure required to participate in the Medicare prescription drug program, including software programs and communication materials.
You may also be interested in...
The companies' combined specialty drug sales were about $4.3 bil. in 2004. The acquisition puts Medco in a position to take a large share of Medicare Part B drug business in addition to its stake in the Part D outpatient drug benefit.
The US FDA appears to have concerns about the device used to administer the vaccine.
Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.